RSV

Jason S McLellan1, Man Chen, Sherman Leung

  • 1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. mclellanja@niaid.nih.gov

Science (New York, N.Y.)
|April 27, 2013
PubMed
概括

研究人员确定了针对呼吸道同胞病毒 (RSV) 融合 (F) 糖蛋白的强有力的预注射特异性抗体. 这些抗体将F蛋白锁定在其预注液状态中,揭示了疫苗和治疗开发的新脆弱性.